Home Tags Merck

Tag: Merck

Merck climbs after announcing massive growth for its top cancer drug, which is now on pace to generate $10 billion a year

Keytruda sales rose 58%, making $2.63 billion in the second quarter. The drug's success pushes Merck ahead of its rival Bristol-Myers Squibb.
Iora Health CEO Rushika Fernandopulle made our list of 10 people transforming healthcare.

Dispensed: Introducing Business Insider’s 10 people transforming healthcare

Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.
Regulators at the FDA will hold a meeting in April on CBD.

Dispensed: Layoffs at Clover Health, a troubling marijuana-linked syndrome, and what’s ahead for the exploding gene therapy field

Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.

Pharma companies want the government to do something about high drug prices, so long as it’s not forcing them to lower their drug prices

Pharmaceutical executives seemed to reach a consensus that it'll take government action to solve the conundrum of how we get to lower drug prices.
Chairman and CEO of Merck & Co., Kenneth Frazier, takes part in a panel discussion during the Clinton Global Initiative's annual meeting in New York, September 27, 2015.

The CEO of Merck has an ominous warning for the middlemen who stand between drug makers and patients

Merck CEO Kenneth Frazier thinks something has to change within the pharmaceutical industry to fix the issue of drug pricing. "I don't understand where we live in a world where 50% of the value goes to supply chain," Frazier said at an event at the Economic Club of New York.

Merck’s board just changed the rules to keep its CEO on board after he turns 65

New Jersey-based pharmaceutical giant Merck said Wednesday that its board of directors had overturned a policy requiring CEOs to retire when they turn 65, allowing Frazier to stick around past December 2019.

Pharma giant Merck just lowered the prices of some of its medications

Merck said Thursday that it would lower the price of some of its medications including lowering the price of its hepatitis C drug Zepatier by 60%.

2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner

The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.

‘We are going to have lung cancer patients living longer and better’: A new kind of cancer treatment is about to change how we treat the d...

Cancer-drug makers found that using immunotherapy in combination with other drugs did a better job of treating lung cancer than chemotherapy alone.

We’re about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated

On Monday, three big players in the growing field of cancer immunotherapy are sharing data that could change how we treat lung cancer.